Revivo Therapeutics is an emerging pharmaceutical company based in Durham, North Carolina. They are developing a new class of therapeutic agents that target neurobehavioral function, cognitive enhancement, and the reduction of disease progression in major neurological diseases, particularly Alzheimer's Disease. Their lead candidate, RIV-1061, has completed phase I trials, and they have two other candidates in preclinical stages. Their therapeutic agents harness the neuroprotective and GABA-mimetic activities of a methylthiazole pharmacophore to address synaptic dysfunction and provide neuroprotection against neuronal loss. Their goal is to improve memory, reduce behavioral symptoms, and slow down disease progression in Alzheimer's patients.